The Impact of Glucagon-Like Peptide-1 Agonists on Hip and Knee Arthroplasty and Perioperative Considerations

被引:5
|
作者
Jacofsky, David J. [1 ]
Springer, Bryan D. [2 ,3 ]
Mont, Michael A. [4 ]
Ushakumari, Deepu S. [5 ]
Sladen, Robert N. [6 ]
机构
[1] CORE Inst, Phoenix, AZ 85023 USA
[2] OrthoCarolina Hip & Knee Ctr, Charlotte, NC USA
[3] Atrium Musculoskeletal Inst, Charlotte, NC USA
[4] Rubin Inst Adv Orthoped, Baltimore, MD USA
[5] Scope Anesthesia North Carolina, Charlotte, NC USA
[6] Columbia Univ, Med Ctr, Crit Care Anesthesiol, Irving, NY USA
关键词
glucagon-like peptide-1 agonists; total hip and knee; perioperative management; diabetes; obesity; MORBIDLY OBESE;
D O I
10.1016/j.arth.2023.12.002
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Glucagon-Like Peptide agonists have traditionally been used for glycemic control in diabetic patients. However, there has been a dramatic rise in their utilization for weight loss management. As such, arthroplasty surgeons will encounter an increasing number of patients on these medications, and therefore it is important to understand the implications of their use in the perioperative period. This review will describe the pharmacological actions of these medications as well as the impact on hip and knee arthroplasty patients, and considerations for perioperative management. Because of the rapid adaption and utilization of these drugs, the science is evolving at a fast pace. More and longer-term studies are needed to truly understand the impact of these medications on total joint arthroplasty utilization and in management of these patients in the perioperative period. (c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:1455 / 1458
页数:4
相关论文
共 50 条
  • [21] Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
    Delgado, A.
    Velosa, J.
    Avelar, R.
    Franco, J.
    Heitor, M.
    EUROPEAN PSYCHIATRY, 2021, 64 : S775 - S775
  • [22] Glucagon-like peptide-1 receptor agonists and safety in the preconception period
    Minis, Evelyn
    Stanford, Fatima Cody
    Mahalingaiah, Shruthi
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2023, 30 (06) : 273 - 279
  • [23] Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
    Baggio, Laurie L.
    Drucker, Daniel J.
    MOLECULAR METABOLISM, 2020, 46
  • [24] Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy
    Dhanapalaratnam, Roshan
    Issar, Tushar
    Poynten, Ann M.
    Milner, Kerry-Lee
    Kwai, Natalie C. G.
    Krishnan, Arun V.
    JOURNAL OF NEUROPHYSIOLOGY, 2025, 133 (01) : 14 - 21
  • [25] Glucagon-Like Peptide-1 Receptor Agonists-Use in Clinical Practice
    Trico, Domenico
    Solini, Anna
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 328 - 336
  • [26] Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy
    Finkle, Johanna
    Brost, Brian C.
    OBSTETRICS AND GYNECOLOGY, 2025, 145 (03) : 286 - 296
  • [27] Potential kidney protective effects of glucagon-like peptide-1 receptor agonists
    Trevella, Philippa
    Ekinci, Elif I.
    Macisaac, Richard J.
    NEPHROLOGY, 2024, 29 (08) : 457 - 469
  • [28] Treating Reproductive-Aged Women With Glucagon-Like Peptide-1 Receptor Agonists: What Are the Clinical Considerations?
    Sharma, Garima
    CIRCULATION, 2024, 150 (19) : 1487 - 1489
  • [29] Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health
    Sabina, Michael
    Alsamman, M. Mrhaf
    CARDIOLOGY RESEARCH, 2024, 15 (01) : 1 - 11
  • [30] Glucagon-Like Peptide-1 Receptor Agonists During Electroconvulsive Therapy: Case Report With Evolving Concerns and Management Considerations Reply
    Antongiorgi, Zarah
    Espinoza, Randall
    JOURNAL OF ECT, 2024, 40 (03) : 220 - 220